Gelesis is a consumer-centered biotherapeutics company with focus on the developing a novel hydrogel platform technology to treat overweight, obesity, and chronic diseases related to the GI pathway. Gelesis received the U.S. FDA clearance for its lead product candidate PLENITY, as an aid for weight management in overweight and obese adults with a Body Mass Index (BMI) of 25-40 kg/m², when used in conjunction with diet and exercise. PLENITY was also granted a CE mark. Additionally, Gelesis’s portfolio includes potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation. Gelesis is a publicly traded company listed on the New York Stock Exchange (NYSE:GLS). For more information about Gelesis, please visit www.gelesis.com.
VAXIMM is a privately held, Swiss/German biotech company that is developing oral T- cell immunotherapies for patients suffering from cancer. VAXIMM’s product platform is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients’ cytotoxic T-cells to target specific structures of the tumor and it can be readily adapted to target a wide range of cancer-related antigens. VAXIMM is headquartered in Basel, Switzerland and its wholly-owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, is responsible for the company’s development activities. For more information about VAXIMM, please visit www.vaximm.com.
Neurelis is a privately-held San Diego-based specialty pharmaceutical company organized to license, develop, and commercialize product candidates for epilepsy and the broader central nervous system (CNS) market. Neurelis is leveraging its expertise in the development and commercialization of CNS compounds and strong relationships with leading researchers and clinicians in these markets to advance unique product candidates, such as NRL-1 for the treatment of acute repetitive or cluster seizures, to address significant unmet medical needs. For more information about Neurelis, please visit www.neurelis.com.
Helius Medical Technologies is a neurotech company in the medical device industry, focused on neurological wellness. With the unique, noninvasive platform technologies, the company is working to expand treatment options for patients by amplifying the brain’s ability to heal itself. Helius Medical Technologies is a publicly traded company listed on NASDAQ (HSDT) in the United States. For more information about Helius Medical Technologies, please visit www.heliusmedical.com.
Blueberry Therapeutics is a pharmaceutical company focused on the discovery, development and commercialisation of high value medicines for the treatment of common dermatological conditions. It applies innovative technologies to improve the delivery of existing drugs through the skin and nail. This enables better efficacy, safety and patient compliance while reducing drug dosage and cost of goods. The company has a de-risked portfolio of best-in-class clinical and preclinical assets addressing high value and poorly served indications in dermatology. For more information about Blueberry Therapeutics, please visit www.blueberrytherapeutics.com.
Destiny Pharma is a clinical stage, biotechnology company focused on the development of novel medicines that represent a new approach to the treatment of infectious disease. These potential new medicines are being developed to address the need for new drugs for the prevention and treatment of life-threatening infections caused by antibiotic resistant bacteria, often referred to as superbugs. Tackling anti-microbial resistance has become a global imperative recognized by the WHO. Destiny Pharma is a public traded company listed on London Stock Exchange’s Alternative Investment Market (AIM: DEST). For more information about Destiny Pharma, please visit www.destinypharma.com.
Acticor Biotech, a France clinical-stage biotechnology company, is a spin-off company from INSERM (French National Institute of Health and Medical Research) founded in November 2013, dedicated to developing an innovative first-in-class treatment for cardiovascular emergencies, with a primary focus on Acute Ischemic Stroke. Acticor Biotech is built upon the expertise and the results of researches conducted by its founders: Dr. Martine Jandrot- Perrus at INSERM Paris and Professor Philippe Billiald at Paris-Sud University. For more information about Acticor Biotech, please visit www.acticor-biotech.com.
